SLC5A2 and hydrops fetalis: In the chronic HF setting, both experimental and human data have supported that SGLT-2 inhibitors shift myocardial fuel utilization from glucose towards the consumption of free fatty acids, ketone bodies and branched-chain amino acids, without an increase in the risk for significant ketosis, thus improving myocardial energetics, LV remodeling and function [45,46].